Results 191 to 200 of about 40,178 (264)

Radiotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: Current Evidence and Future Directions. [PDF]

Curr Oncol
Resende Salgado L, Zaytoun O, Rabie A, Murphy N, Nehlsen A, Hsieh K, Dovey Z, Aamir A, Sindhu KK.   +8 more
europepmc   +1 more source

Postoperative Neutrophil-to-Albumin Ratio as a Prognostic Marker for Patients with Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Observational Cohort Study. [PDF]

Int J Gen Med
Li W, Xiang C, Xie G, Zhang Y.
europepmc   +1 more source

Near infrared ray-guided partial cystectomy using da Vinci Firefly^® technology and intraoperative cystoscopy for urachal cyst, suspected of urachal tumor. [PDF]

Investig Clin Urol
Kurobe M, Ogawa T, Satoh Y, Yamamoto M, Ushijima K, Okamoto K, Numahata D, Ohta T, Takayama T.   +8 more
europepmc   +1 more source

Clinical Outcomes in Bacillus Calmette-Guérin-Exposed Non-Muscle-Invasive Bladder Cancer.

JAMA Netw Open
Giatsoglou M, Chatzistavrou D, Sopczynski JM, Feng G, Li R.   +4 more
europepmc   +1 more source

Redefining Boundaries-Safety of Radiation Therapy in the Presence of Orthotopic Neobladder. [PDF]

Adv Radiat Oncol
Ho A, Dajani S, Yadav P, Kalapurakal J, Kundu S, Meeks J, Sachdev S.   +6 more
europepmc   +1 more source

Laparoscopic stapled partial cystectomy with intraoperative cystourethroscopy for urothelial carcinoma in two dogs. [PDF]

Vet Surg
Griffin MA, Folk C, Buote NJ.
europepmc   +1 more source

Impact of frailty on adverse outcomes after radical cystectomy: a systematic review and meta-analysis. [PDF]

Front Oncol
Fang J, Tan Y.
europepmc   +1 more source

Circulating tumor DNA as a prognostic biomarker in adjuvant nivolumab therapy for high-risk muscle-invasive urothelial carcinoma: insights from CheckMate 274 and beyond. [PDF]

Transl Androl Urol
Yajima S, Masuda H.
europepmc   +1 more source

Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer. [PDF]

Clin Cancer Res
Guercio BJ, Pietzak EJ, Ravichandran V, Chen JF, Shah RH, Peters V, Regazzi AM, Niglio SA, Aggen DH, Funt SA, Donahue TF, Goh AC, Cha EK, Wong P, Richards AL, Cobbs CC, Donat SM, Dalbagni G, Bochner BH, Iyer G, Donoghue MTA, Ostrovnaya I, Al-Ahmadie HA, Rosenberg JE, Teo MY.   +24 more
europepmc   +1 more source

Consolidation enfortumab vedotin and pembrolizumab after cisplatin induction in metastatic urothelial cancer: Outcomes of complete response and bladder preservation. [PDF]

J Int Med Res
Chan KH, Cen P, Shu T, Canfield S, Zhao H, Gonzalez A, Rowe J, Tammisetti V, Ayoub H, Blanco A, Amsbaugh M, Tannir N.   +11 more
europepmc   +1 more source